We are a team of builders, investors and operators with deep women’s health, healthcare and clinical expertise.
Elizabeth Bailey is Co-founder & Managing Director of RH Capital. Throughout her career, Elizabeth has been a passionate advocate of the power of business to drive social change. She has over 20 years of experience in venture capital and supporting early-stage health technology companies. She was a Partner at one of the first impact venture capital funds, Commons Capital, where she managed the healthcare portfolio, including: Claros Diagnostics (acquired by OPKO), CodeRyte (acquired by 3M), HistoRx (acquired by Genoptix), Medical Metrx Solutions (acquired by AIG) and TelaDoc (IPO: TDOC). Prior to joining RH Capital, Elizabeth served as the Founding Director of CAMTech at Massachusetts General Hospital, where she built a global program to accelerate medtech innovation and catalyze new health startups. Elizabeth holds a Masters in Public Policy from Harvard University’s Kennedy School of Government and a B.A. from Brown University.
Why women’s health?
“I think Maya Angelou said it best. “I’m interested in women’s health because I’m a woman. I’d be a darn fool not to be on my own side.”
Stasia Obremskey is Co-founder and Managing Director of RH Capital. She believes the world is a better place when you educate women and give them the tools to manage their unique health care needs. This belief has inspired her work in women’s health. After working professionally for over twenty-five years as a trusted advisor to non-profit organizations and start-up companies, and establishing herself as an impact investor in women’s reproductive health, she joined Rhia Ventures at its inception in 2018. Stasia holds a bachelor’s degree in Business Administration with a concentration in finance from the University of Notre Dame and an MBA from the Harvard Graduate School of Business.
Why women’s health?
“While women make up 50% of the population, they birth 100% of the population and yet their unique healthcare needs have been historically overlooked. I’m passionate about finding innovations to reverse this trend and address the many areas in women’s health still looking for improved and new solutions.”
Alice is a Principal at RH Capital, responsible for leading investments in innovative women’s health companies across the life sciences, digital health and consumer health. Alice has been a women’s health enthusiast throughout her career spanning global health, clinical medicine, and the private sector. Alice was previously a women’s health practice leader and management consultant at McKinsey & Company, where she served biopharma, diagnostics, global public health, and private equity clients across R&D and commercial strategy topics.
Earlier in her career, Alice’s passion to improve lives for the underserved led her to work in East Africa and Asia in reproductive health and family planning with EngenderHealth, Marie Stopes International, and other nonprofits. As a clinician, she focused on women’s health globally and published articles examining healthcare in low-income countries. Alice holds an MBA from Harvard Business School and MD and MPH from the University of Michigan, where she was a Dean’s Merit Scholar. Alice is a frequent speaker on FemTech and women’s health innovation and is a steering committee member for multiple women’s health innovation forums.
Why women’s health?
“I’ve always been drawn to underserved women’s issues, from performing in the Vagina Monologues three times in college to working in rural African villages without running water or electricity to prevent and treat obstetric fistulas. I am now a mother of two and have been a patient myself in many women’s health areas I once aspired to specialize in, having experienced infertility, a medical termination and pregnancy complications. It is a long-standing personal and professional passion of mine to improve lives of women around the world.”
Cassidy Petit is an Analyst at RH Capital. She has always had a passion for technology and entrepreneurship for which inspired her to enter the VC world. Before joining RH Capital, Cassidy spent the past 3.5 years building Hula, a Vermont-based, early-stage technology incubator and venture fund focused on economic development and rural innovation.
Before moving into venture, Cassidy started her career in social work, where she worked with expectant and new mothers in recovery and transitioning out of incarceration. Cassidy graduated from the University of Vermont, where she studied Psychology & Neuroscience.
Why women’s health?
“The U.S. is a world leader in advancing technology, yet we represent one of the worst maternal mortality rates of the industrialized nations. The government and healthcare system continue to fail women to a worsening degree. Women represent half of the population, but women’s health and associated technologies are disproportionately underinvested. I am so excited to be working with the RH Capital team to support technology that is improving access and outcomes for women.”
A team of healthcare trailblazers who work alongside us on investment strategy, due diligence efforts, investment decisions, and portfolio management.
Janice Bourque is Managing Director of Life Sciences for Hercules Capital, a premier specialty public life science companies at all stages of development with $16 billion committed to over 600 life science, technology and renewable energy companies. Deal sizes range from $10m-$300m and included in her portfolio are BIND Bioscience, BioMx, Brickell, Cempra Pharmaceuticals, Codiak Biosciences, Concert Pharmaceutical, Cranford Pharmaceuticals, Dance Pharmaceuticals, deCode/ Eloxx,Genetics, Gamma Medica, Glori Energy, Kaleido Biosciences, Medrobotics, Metuchen Pharmaceuticals, Nabriva Therapeutics, Ninepoint Medical, Quanta Fluid Systems, Pulmatrix, Kaleido, Seres Therapeutics, and Syndax. Previously, Ms. Bourque provided strategic corporate investor fundraising for Commons Capital and Oxford Bioscience Partners for innovative healthcare investments for emerging and developing countries and was Senior Vice President, Group Head-Life Sciences for Comerica Bank. While at Comerica, notable deals that led to several M&A exits included Hypnion/Eli Lilly; Adnexus/Bristol Meyers Squibb; and Morphotek/Eisai Pharmaceuticals.
As President/CEO of the Massachusetts Biotechnology Council (MBC) for 12 years, Ms.Bourque helped ensure that Massachusetts is at the forefront of the biotechnology revolution helping to create the first biotechnology association in the world. Numerous programs and initiatives, now duplicated around the world, were created under her leadership. Ms Bourque held senior managerial positions at Cambridge Medical Technology Corporation and Coopers & Lybrand Emerging Technology Group.
Ms. Bourque is on several corporate boards and their respective committees: Poxel Inc (French public biotech; Audit Committee, Chair of Nominating and Governance ), Bicycle Therapeutics (UK public biotech: Audit and Compensation Committees and Chair of Nominating and Governance), The Village Bank, a $1B mutual bank: (Nominating and Governance Committee, Compensation Committee and Chair of Audit Committee), Commodore Builders (mid-sized construction firm in Boston), Forsyth Institute Advisory committee (only independent institute focused on both oral health research and oral clinical services in the world) and is a member of Women on Corporate Boards. She is also active in her community in Newton MA and serves as co-president of the Crystal Lake Conservancy and Chair of the Board of The Hyde Community Center. Ms. Bourque is a trustee for a privately developed community home for differently-abled young working women and men. She was named one of Boston Magazine’s 100 most influential women and Newton Living Magazine’s 10 most influential women. Ms. Bourque received her MBA degree in finance and accounting and her BS degree in veterinary science from the University of New Hampshire.
Erika Seth Davies is the CEO of Rhia Ventures, which aims to transform the U.S. market for sexual, reproductive, and maternal health into a vibrant and equitable one through its impact investing, ecosystem building, corporate engagement, and narrative change work. She is a seasoned leader with more than 20 years of experience in development and fundraising, program design, collaboration and partnership management, and racial equity advocacy. Erika is the Founder of The Racial Equity Asset Lab (The REAL), a venture that centers racial equity in impact investing and works to shift capital to address the persistent racial wealth gap. She previously served as Vice President of External Affairs at ABFE (Association of Black Foundation Executives) where she designed the SMART Investing Initiative, a field-wide effort to encourage foundations to incorporate a racial equity lens in endowment management practices through increased access for racially diverse- and women-owned investment management firms.
Erika is a Social Entrepreneur in Residence with Common Future and a former Fellow, Equitable Access to Capital Markets in the Fair Finance portfolio of the Beeck Center for Social Impact + Innovation at Georgetown University. She was a member of the inaugural class of the ABFE Connecting Leaders Fellowship program, a recipient of the NYU Wagner School of Public Service IGNITE Fellowship for Women of Color in the Social Sector, and a member of the class of 2017 for Executive Leadership Institute of CFLeads.
Erika most recently was the Associate Director of Philanthropy at McDonogh School and previously served as the Chief of Staff of the Baltimore Community Foundation. She enjoys volunteering and serves as a member of the boards of Impact Hub Baltimore and Baltimore Algebra Project.
Additional positions and activities include serving on Glenmede’s Sustainable and Impact Investing Advisory Council, the Investment Committee for the Nathan Cummings Foundation, the Impact Investing Committee of the Max M. and Marjorie S. Fisher Foundation, Matter Unlimited’s Advisory Board, and the Abortion and Reproductive Health, Rights, and Justice Cohort of Women Leaders for the World.
Her most significant role is that of mother to Ethan and Evelyn.
Stacy is Regional Head of Johnson & Johnson Innovation, West North America and is based in Brisbane, California. In this role, she leads a team of scientific and business leaders to build, advance, and manage a portfolio of co-investments and collaborations spanning the pharmaceutical, consumer health and medical device sectors. Stacy is also responsible for expanding and nurturing the external networks within the innovation community, including academia, venture capital, entrepreneurs and other governmental and private organizations.
Stacy has 25 years of diverse business experience translating innovative science and technology into transformative commercial solutions for patients and consumers. She has held a range of leadership positions in the healthcare, biotech, life sciences, consumer health and digital health sectors as a business development executive, venture capital investor, business and innovation strategist and transactional attorney.
Prior to her position as Regional Head of Johnson & Johnson Innovation, West North America, Stacy was Vice President of Consumer Venture Investments and External Innovation and a team member of Johnson & Johnson Innovation – JJDC, Inc. (JJDC). During her three-year tenure at JJDC, Stacy was globally responsible for the growth and management of the Consumer Health equity portfolio and led consumer health and health technology venture investing on the investment team. Under her leadership, the Consumer Health portfolio grew threefold, adding innovative scientific and technological solutions including branded consumer health products and digital health solutions.
Stacy joined Johnson & Johnson Innovation in 2014 as Senior Director of Consumer Scientific Innovation at the California Innovation Center, where she was responsible for the identification, assessment and execution of partnerships and collaborations to onboard strategic value assets for the Consumer Health sector.
Prior to joining Johnson & Johnson, Stacy was a partner at Physic Ventures, a venture capital firm investing in health and sustainability, where she led investments in personalized health solutions that empower consumers to improve their health and wellbeing. Stacy has also been active in the design and execution of science and technology-enabled innovation strategies, business incubation and spin-off opportunities, advising senior management of global enterprises in the consumer product goods industry and pre-commercial and commercial-stage start-ups in the personalized health and medical technology sectors. Prior to joining Physic Ventures, Stacy held leadership positions in the business development groups at Genentech and Third Wave Technologies and was a technology transactions attorney at Wilson, Sonsini, Goodrich & Rosati.
Stacy earned her B.A. in Sociology from the University of Pennsylvania and received her J.D. from Vanderbilt Law School.
Anula Jayasuriya is a successful private equity executive and venture capitalist whose background combines deep business, scientific and medical knowledge with broad clinical, industry, entrepreneurial, and investment experience. Anula was among the first investors to recognize the untapped opportunity in the unmet needs in women’s health (WH). Integrating her passion with her investing expertise, in 2013 Anula founded EXXclaim Capital, an early-stage venture fund focused on catalyzing innovation, entrepreneurship and investment in Women’s Health. EXXclaim has invested in a portfolio of diverse WH companies ranging from digital health, medical devices, and diagnostics to consumer products.
EXXclaim’s first investment, nVision Medical, was acquired in 2018 by Boston Scientific Inc. validating the significant business opportunity in women’s health. In 2006 Anula co-founded the “Evolvence India Life Science Fund” the very first fund in India to focus exclusively on health care and invest in Indian pharmaceutical, biotechnology, medical device and contract services companies. The fund garnered attractive returns to investors.
Anula was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German/US venture capital firm TVM, in San Francisco. Her prior positions include VP Business Development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation. Anula serves on the boards of several emerging technology companies, and on two non-profit boards. Anula received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and received an MBA with distinction from Harvard Business School. Anula also holds a M. Phil. in pharmacology from the University of Cambridge, in England.
Amy Belt Raimundo is Managing Director of Kaiser Permanente Ventures. She is also currently an Independent Board Director at NuVasive Inc (NASDAQ: NUVA). Amy has a 15 year history of venture investing in medtech, diagnostics, healthcare information technology and digitized services including with Advanced Technology Ventures, Covidien Ventures and Convey Capital. In those roles, she has led diligence, made investments and assumed board roles in over 20 companies. Amy has also held a variety of operating roles including Chief Business Officer at Evidation Health, interim general management at Covidien, VP Reimbursement for Endogastric Solutions and multiple product management roles at Guidant Corporation. She spent several years as a management consultant at APM/CSC Healthcare where she optimized clinical guidelines, staffing and workflows for major health systems. Amy is a Kauffman Venture Fellow and holds a BA in Economics from Yale University and an MBA from the University of California at Berkeley.
Jenny is currently a Managing Partner at Adjuvant Capital, a life sciences investment fund dedicated to mid- to late-stage research and development of products addressing significant global health challenges affecting lower- and middle-income countries. Adjuvant’s portfolio spans across drugs, vaccines, medical devices and diagnostics for high-burden infectious disease, sexual and reproductive health. Jenny currently serves on the boards of Antiva Biosciences (US), 54gene (Nigeria) and ChromaCode (US) and as a board observer on Excision Biotherapeutics (US).
Prior to Adjuvant, Jenny was a Partner at the Bill & Melinda Gates Foundation Strategic Investment Fund where she led transactions across the foundation’s focus areas in global health, agriculture, nutrition, and education. She has always been passionate about improving the health and lives of those living in low-resourced settings and spent time working in Kenya and China. In Kenya, Jenny was a volunteer consultant for Technoserve, a non-profit business consultancy for small-holder farmers and small to medium businesses.
Jenny has worked in finance for over 20 years, beginning as an investment banker advising corporate clients in mergers and acquisitions and debt and equity financings at Goldman Sachs’ Hong Kong, New York, and San Francisco offices. She also serves on the board of Resurge International, a global non-profit organization delivering complex reconstructive surgical care to low-resourced patients and on the advisory board of the Harvard TH Chan School of Public Health Magazine.
Jenny graduated magna cum laude from Harvard University with an AB in History of Science. She lives with her husband and two children in San Francisco.
The Women’s Health Innovation Council (WHIC) was created with support from the Bill & Melinda Gates Foundation to provide clinical and technical expertise to inform investment decisions and to support portfolio companies. During our due diligence process, we assemble experts with expertise in research, clinical, regulatory, product development and design, manufacturing, and other relevant fields and conduct in-depth interviews to gain important insights.